Testing version — LOERadar is in active testing. Features and data may change.
SERAX (OXAZEPAM) | LOERadar
SERAX
NDA
OXAZEPAM | N015539 | ALPHARMA US PHARMACEUTICALS DIVISION
4 strengths0 unique patents0 unique exclusivities
PTAB Proceedings
No IPR/PGR/CBM challenges found at the Patent Trial and Appeal Board
Hatch-Waxman Litigation
Para IV certification filed but no ANDA patent litigation cases (NOS 835) matched from PACER. Litigation may be pending or filed under a different caption.
Citizen Petitions
No FDA citizen petitions matched from Regulations.gov
Products (4)
Sort:
#002 — 10MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
RLD
0 patents0 exclusivities▴
CAPSULE;ORAL | Approved: Approved Prior to Jan 1, 1982
No patent or exclusivity listings for this strength.
#004 — 15MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
RLD
0 patents0 exclusivities▾
CAPSULE;ORAL | Approved: Approved Prior to Jan 1, 1982
#006 — 30MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
RLD
0 patents0 exclusivities▾
CAPSULE;ORAL | Approved: Approved Prior to Jan 1, 1982
#008 — 15MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
0 patents0 exclusivities▾
TABLET;ORAL | Approved: Approved Prior to Jan 1, 1982